Jasper Therapeutics (JSPR)
NASDAQ:JSPR
US Market
Holding JSPR?
Track your performance easily

Jasper Therapeutics (JSPR) Income Statement

583 Followers

Jasper Therapeutics Income Statement

Last quarter (Q3 2024), Jasper Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Jasper Therapeutics's net income was $-18.64M. See Jasper Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
-$ 9.00M-$ 9.00M-
Cost of Revenue
----$ -7.05K
Gross Profit
-$ 9.00M-$ 9.00M$ 7.05K
Operating Expense
$ 73.07M$ 68.86M$ 51.20M$ 36.83M$ 20.68M
Operating Income
$ -73.07M$ -68.86M$ -51.20M$ -36.83M$ -20.68M
Net Non Operating Interest Income Expense
$ 5.65M$ 4.95M$ 2.20M$ -80.00K$ -111.00K
Other Income Expense
$ -133.00K$ 557.00K$ -13.51M$ -6.20M$ -383.15K
Pretax Income
$ -58.06M$ -64.47M$ -37.69M$ -30.64M$ -31.67M
Tax Provision
-$ -13.54M$ -7.91M$ -6.43M$ 38.45K
Earnings From Equity Interest Net Of Tax
-$ 700.00K---
Net Income Common Stockholders
$ -66.84M$ -128.93M$ -37.69M$ -30.64M$ -31.67M
Basic EPS
$ -5.31$ -6.18$ -1.03$ -26.90-
Diluted EPS
$ -5.31$ -6.18$ -1.03$ -26.90$ 0.10
Basic Average Shares
$ 51.88M$ 10.44M$ 36.48M$ 1.14M$ 1.00M
Diluted Average Shares
$ 51.99M$ 10.44M$ 36.48M$ 266.04K$ 1.00M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 73.07M$ 68.86M$ -51.20M$ 36.83M$ 928.35K
Net Income From Continuing And Discontinued Operation
$ -66.84M$ -64.47M$ -37.69M$ -30.64M$ -31.67M
Normalized Income
$ -28.26M----
Interest Expense
-----
EBIT
$ -68.66M$ -77.76M$ -37.69M$ -36.83M$ -20.68M
EBITDA
$ -67.35M$ -76.66M$ -36.38M$ -36.46M$ -20.68M
Currency in USD

Jasper Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis